JMP Securities analyst Reni Benjamin maintained a Hold rating on Deciphera Pharmaceuticals (DCPH – Research Report) today. The company’s shares closed last Monday at $9.04, close to its 52-week low of $7.63.
According to TipRanks.com, Benjamin ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -9.2% and a 33.2% success rate. Benjamin covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Iovance Biotherapeutics, and Allogene Therapeutics.
Currently, the analyst consensus on Deciphera Pharmaceuticals is a Hold with an average price target of $12.25.
See today’s best-performing stocks on TipRanks >>
Deciphera Pharmaceuticals’ market cap is currently $522.2M and has a P/E ratio of -1.88.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Deciphera Pharmaceuticals, Inc. operates as a biotechnology company which develops and manufactures kinase inhibitor treatments for cancer by cutting off the ability of tumor cells to thrive and spread. The company designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, and other solid tumors. It also develops two other clinical-stage drug candidates, DCC-3014 and rebastinib, as immuno-oncology kinase, inhibitors targeting the kinases CSF1R, and TIE2 kinas. The company was founded by Peter A. Petillo and Daniel L. Flynn in November 2003 and is headquartered in Waltham, MA.
Read More on DCPH:
